KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Enterprise Value (2016 - 2026)

Boston Scientific's Enterprise Value history spans 18 years, with the latest figure at -$1.2 billion for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 146.54% to -$1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.2 billion, a 146.54% decrease, with the full-year FY2025 number at -$1.7 billion, down 362.73% from a year prior.
  • Enterprise Value hit -$1.2 billion in Q1 2026 for Boston Scientific, up from -$1.7 billion in the prior quarter.
  • Over the last five years, Enterprise Value for BSX hit a ceiling of -$167.0 million in Q2 2023 and a floor of -$2.7 billion in Q2 2024.
  • Historically, Enterprise Value has averaged -$931.1 million across 5 years, with a median of -$617.0 million in 2023.
  • Biggest five-year swings in Enterprise Value: skyrocketed 89.68% in 2022 and later tumbled 1501.8% in 2024.
  • Tracing BSX's Enterprise Value over 5 years: stood at -$928.0 million in 2022, then surged by 33.51% to -$617.0 million in 2023, then skyrocketed by 39.55% to -$373.0 million in 2024, then crashed by 362.73% to -$1.7 billion in 2025, then rose by 29.72% to -$1.2 billion in 2026.
  • Business Quant data shows Enterprise Value for BSX at -$1.2 billion in Q1 2026, -$1.7 billion in Q4 2025, and -$1.0 billion in Q3 2025.